
Revvity Signals
AI-powered R&D data capture, analytics, and collaboration for pharma, biotech, chemicals, materials, and food science.
Overview
Revvity Signals Software is an AI-powered, cloud-native scientific SaaS platform serving researchers and organizations across Pharma, Biotech, Chemicals and Materials, Food Science, Flavors and Fragrances, Energy and Petrochemicals, and Electronics. Originally founded as CambridgeSoft in 1986 and acquired by Revvity, Inc. in 2011, the company has grown to serve more than one million end-users worldwide across 4,000+ customer organizations, with operations in the United States, Canada, Europe, and Asia. As a division of Revvity, Inc.—a global life sciences company with approximately 11,000 employees and revenue of roughly $3.8 billion—Revvity Signals Software brings over 40 years of scientific software development expertise to its enterprise platform.
The company's mission is to empower scientists to capture, organize, analyze, and visualize critical R&D data—from initial drug discovery and development through biomarker discovery, patient stratification, and clinical trial monitoring—enabling actionable insights in an automated, predictive, and scalable way. Revvity Signals is committed to delivering one of the most comprehensive suites of enterprise scientific software solutions available anywhere in the world.
Core Products and Modules
- Signals One™ – The first AI-enhanced, unified, cloud-native R&D solution designed to reduce complexity and enable seamless collaboration. It serves as the foundational environment for capturing, managing, and sharing experiment data and research notes securely. A dedicated configuration for Materials Science helps teams capture, organize, and analyze formulation and specialty chemicals data to accelerate development and shorten time-to-market.
- Signals Notebook™ – The premier cloud-native electronic lab notebook (ELN) for biologists and chemists, enabling collaboration, data capture, organization, sharing, and exploration. It is the only ELN with a native integration with ChemDraw™ and Spotfire®.
- ChemDraw™ – The industry's most trusted chemical drawing and communication solution, in continuous development since 1985. ChemDraw provides a complete suite for creating, managing, sharing, and presenting chemistry research and discoveries, and is used by over one million scientists worldwide.
- Signals Clinical™ – An AI-assisted clinical data review workspace that unifies listings, queries, and medical monitoring in a single environment. It streamlines clinical data workflows, reduces time spent preparing data for analytics, and delivers rapid clinical insights, with Spotfire® built in for flexible, study-specific analysis and compliance-ready oversight.
- Signals Xynthetica™ – An AI-powered design platform that converges computational design with experimental science, representing a significant advancement in synthesis and molecular design workflows.
- Signals BioDesign – An enterprise SaaS solution that streamlines molecular biology workflows, with a focus on core cloning and high-throughput plasmid modeling.
- Signals Synergy – A solution designed to enhance collaboration and information exchange between pharmaceutical sponsors and contract research organizations (CROs).
- Signals LabGistics – A platform for streamlining scientific workflows across the entire drug development lifecycle.
- Spotfire® – Revvity Signals is the exclusive provider of Spotfire® for scientific and clinical R&D applications, empowering teams to drive data-driven decisions through advanced visual analytics.
- Lilly TuneLab™ – A federated learning program developed in partnership with Lilly, enabling scientists to access advanced AI-powered property predictions while preserving intellectual property.
Industry Solutions
- Pharma and Biotech – Cutting-edge informatics solutions tailored to the unique needs of pharmaceutical and biotechnology organizations, supporting drug discovery from small molecules to large modalities, eliminating data silos, and reducing manual tasks.
- Chemicals and Materials – Data capture, organization, and analytics solutions to advance specialty chemicals and formulations development, accelerating product-to-market cycles.
- Food, Flavor, and Fragrance – Data capture and analytics tools to advance food and flavor recipe development and speed products to market.
- Clinical Analytics – Solutions to inform clinical development decisions and enable visual data exploration through Signals Clinical and Spotfire, with self-service access to analytics-ready data.
- Drug Discovery – A cloud software suite that brings together every scientific discipline—from small molecules to large modalities—to accelerate the discovery process.
Platform Capabilities and Notable Strengths
- AI-enhanced capabilities embedded across the platform, including Agent Signals for conversational research assistance and federated learning for IP-preserving AI model training.
- Cloud-native, SaaS architecture enabling secure, scalable deployment for enterprise R&D organizations globally.
- The only scientific ELN platform with a native ChemDraw integration, providing a seamless chemistry authoring experience within the lab notebook environment.
- Exclusive partnership with Spotfire® for scientific and clinical analytics, enabling rich data visualization and self-service analytics across R&D workflows.
- Comprehensive coverage of the R&D lifecycle—from early research and data capture through clinical trial analytics and regulatory-ready reporting.
- Serves customers across more than 190 countries through its parent company Revvity, Inc., which is listed on the S&P 500.
- A global team of approximately 720 dedicated software employees, supported by a broader Revvity organization of around 11,000 people worldwide.
With a legacy spanning nearly four decades and a continuously expanding portfolio of AI-powered scientific software, Revvity Signals Software stands as one of the most comprehensive and trusted informatics platforms available to the global life sciences and applied sciences communities.